Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
Latest Information Update: 22 Aug 2022
Price :
$35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 26 Jul 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2020 Planned End Date changed from 15 Dec 2020 to 15 Dec 2021.
- 12 Jul 2019 Planned primary completion date changed from 15 Dec 2018 to 15 Dec 2019.